La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Guangxi Wuzhou Zhongheng GroupLtd Résultats passés
Passé contrôle des critères 1/6
Guangxi Wuzhou Zhongheng GroupLtd's earnings have been declining at an average annual rate of -43.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 6.8% per year. Guangxi Wuzhou Zhongheng GroupLtd's return on equity is 1.3%, and it has net margins of 4.8%.
Informations clés
-43.3%
Taux de croissance des bénéfices
-43.3%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 10.9% |
Taux de croissance des recettes | -6.8% |
Rendement des fonds propres | 1.3% |
Marge nette | 4.8% |
Prochaine mise à jour des résultats | 31 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
Investors Don't See Light At End Of Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Tunnel
Jun 19Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Apr 05Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Has Debt But No Earnings; Should You Worry?
Mar 15Ventilation des recettes et des dépenses
Comment Guangxi Wuzhou Zhongheng GroupLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Mar 24 | 3,233 | 156 | 1,574 | 154 |
31 Dec 23 | 3,097 | 84 | 1,714 | 154 |
30 Sep 23 | 2,989 | 54 | 1,599 | 126 |
30 Jun 23 | 3,003 | 59 | 1,643 | 128 |
31 Mar 23 | 2,743 | -24 | 1,554 | 114 |
31 Dec 22 | 2,714 | 79 | 1,445 | 135 |
30 Sep 22 | 2,383 | -68 | 1,574 | 197 |
30 Jun 22 | 2,469 | 70 | 1,557 | 202 |
31 Mar 22 | 2,648 | 212 | 1,590 | 215 |
31 Dec 21 | 3,162 | 307 | 1,995 | 198 |
30 Sep 21 | 3,419 | 656 | 2,342 | 190 |
30 Jun 21 | 3,812 | 590 | 2,643 | 173 |
31 Mar 21 | 3,847 | 588 | 2,663 | 152 |
31 Dec 20 | 3,676 | 563 | 2,326 | 132 |
30 Sep 20 | 3,988 | 596 | 2,150 | 57 |
30 Jun 20 | 3,747 | 700 | 1,989 | 52 |
31 Mar 20 | 3,923 | 727 | 2,187 | 53 |
31 Dec 19 | 3,814 | 745 | 2,438 | 63 |
30 Sep 19 | 3,589 | 713 | 2,488 | 37 |
30 Jun 19 | 3,602 | 640 | 2,558 | 38 |
31 Mar 19 | 3,508 | 669 | 2,496 | 51 |
31 Dec 18 | 3,299 | 613 | 2,296 | 45 |
30 Sep 18 | 2,913 | 552 | 1,950 | 52 |
30 Jun 18 | 2,624 | 555 | 1,600 | 88 |
31 Mar 18 | 2,305 | 577 | 1,199 | 59 |
31 Dec 17 | 2,048 | 605 | 885 | 47 |
30 Sep 17 | 2,153 | 587 | 895 | 50 |
30 Jun 17 | 1,880 | 596 | 676 | 0 |
31 Mar 17 | 1,734 | 496 | 574 | 0 |
31 Dec 16 | 1,670 | 489 | 532 | 0 |
30 Sep 16 | 1,172 | 354 | 348 | 0 |
30 Jun 16 | 1,016 | 181 | 395 | 0 |
31 Mar 16 | 997 | 440 | 503 | 0 |
31 Dec 15 | 1,343 | 520 | 669 | 0 |
30 Sep 15 | 1,878 | 1,457 | 740 | 0 |
30 Jun 15 | 2,473 | 1,723 | 960 | 0 |
31 Mar 15 | 3,027 | 1,615 | 1,158 | 0 |
31 Dec 14 | 3,214 | 1,595 | 1,370 | 0 |
30 Sep 14 | 3,613 | 920 | 1,692 | 0 |
30 Jun 14 | 4,236 | 859 | 2,366 | 0 |
31 Mar 14 | 4,245 | 815 | 2,440 | 0 |
31 Dec 13 | 3,997 | 743 | 2,327 | 0 |
30 Sep 13 | 3,768 | 809 | 2,137 | 0 |
Des revenus de qualité: 600252 has a large one-off loss of CN¥77.5M impacting its last 12 months of financial results to 31st March, 2024.
Augmentation de la marge bénéficiaire: 600252 became profitable in the past.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 600252's earnings have declined by 43.3% per year over the past 5 years.
Accélération de la croissance: 600252 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Bénéfices par rapport au secteur d'activité: 600252 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Rendement des fonds propres
ROE élevé: 600252's Return on Equity (1.3%) is considered low.